General Information of Drug (ID: DMOQ63E)

Drug Name
Rottlerin Drug Info
Synonyms
Kamalin; Mallotoxin; R 5648; BMK1-F10; (E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one; (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; 1-[6-(3-Acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl]-3-phenyl-propenone; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Preclinical [1]
Cross-matching ID
PubChem CID
5281847
ChEBI ID
CHEBI:8899
CAS Number
CAS 82-08-6
TTD Drug ID
DMOQ63E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Protein kinase C (PRKC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Synthetic hypericin DMXU4ON Virus infection 1A24-1D9Z Phase 3 [3]
APH-0812 DM756GE Human immunodeficiency virus-1 infection 1C62 Phase 2 [4]
CYCLOPLATAM DMXR8WN Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
AEB07 DMJVN89 Transplant rejection NE84 Phase 2 [6]
HO/03/03 DMA6HQJ Diabetic foot ulcer BD54 Phase 2 [7]
Bryostatin-1 DM1JOXY Alzheimer disease 8A20 Phase 2 [8]
LXS196 DM65MEL Solid tumour/cancer 2A00-2F9Z Phase 1/2 [9]
SAFINGOL DMBGUDR Psoriasis vulgaris EA90 Phase 1 [10]
GCC-1290K DMJ7WRI Parkinson disease 8A00.0 Phase 1 [11]
AEB701 DM8I4G0 Melanoma 2C30 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C (PRKC) TTYVX59 NOUNIPROTAC Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2611).
2 Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
3 Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
4 Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
5 Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
6 What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
7 WO patent application no. 2014,0853,81, Pharmaceutical combinations.
8 Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
11 Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
12 Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.